中文
北京科兴网站被迫暂停使用
北京科兴网站被迫暂停使用
北京时间2018年 4月30日，科兴控股生物技术有限公司（NASDAQ: SVA），一家领先的中国生物制药公司宣布，未名生物医药有限公司代表及公司控股子公司北京科兴董事长潘爱华在未获得授权的前提下，不恰当地夺取了公司网站（www.sinovac.com / www.sinovac.com）的控制权并关闭了该网站。出于谨慎的考虑, 公司决定暂时停止网站访问, 以避免因任何进一步的未经授权的访问或篡改而误导对网站信息感兴趣的利益相关者。
对公司网站的不当控制是潘先生和未名对科兴业务干预的又一明显证明。
公司建议所有的监管机构、股东、客户、员工以及其他相关机构在公司重新获得网站控制权前，仅通过PR Newswire和美国证监会获得官方英文信息，通过官方微信公众号（疫苗之益，微信号：SinovacBiotech）获得官方中文信息。
Sinovac Temporarily Blocks Access to Its Websites
BEIJING, April 30, 2018 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that Aihua Pan, the Chairman of the Board of the Company's controlled Chinese subsidiary, Sinovac Biotech Co., Ltd. ("Sinovac Beijing"), who was appointed by Sinobioway Biomedicine Co., Ltd. ("Sinobioway"), the minority shareholder of Sinovac Beijing, inappropriately and without authorization seized control of the Company's websites, www.sinovac.com and www.sinovac.com. Out of an abundance of caution, the Company has temporarily blocked the access to the websites to avoid any further unauthorized access or tampering that could mislead any interested stakeholders.
The misappropriation of the Company's websites is another blatant attempt by Mr. Pan and Sinobioway to interfere with Sinovac's business.
The Company advises all regulators, shareholders, customers, employees, and other interested stakeholders that authorized English messages from the Company will be distributed via the Company's PR Newswire account and filings with the U.S. Securities and Exchange Commission and authorized Chinese messages from the Company will be distributed via the Company's official WeChat public account (account name: SinovacBiotech) until the Company regains control of its websites.
关于SINOVAC科兴
科兴控股生物技术有限公司（Sinovac Biotech Ltd.，SINOVAC科兴）是中国领先的生物高新技术企业，以“为人类消除疾病提供疫苗”为使命，致力于人用疫苗及其相关产品的研究、开发、生产和销售，为全球疾病预防控制提供服务。
SINOVAC科兴研制的疫苗主要包括针对病毒性肝炎、流感、肺炎、脊髓灰质炎、水痘等常见传染病的疫苗以及针对SARS、甲型H5N1高致病性禽流感、甲型H1N1流感大流行、EV71相关手足口病、新型冠状病毒感染等新发、突发传染病的疫苗。
SINOVAC科兴不断探索国际市场的机遇，已经向数十个国家及国际组织出口疫苗。公司甲肝灭活疫苗、Sabin株脊髓灰质炎灭活疫苗及水痘减毒活疫苗已通过世界卫生组织预认证，新型冠状病毒灭活疫苗在新冠大流行期间被世界卫生组织列入紧急使用清单，疫苗质量管理体系获国际组织和多国药监部门认可。